相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma
Kimiko Koiwai et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2021)
Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia
Andrew H. Wei et al.
LEUKEMIA (2021)
Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches
Juan Jose Lahuerta et al.
BLOOD ADVANCES (2021)
Roadmap to cure multiple myeloma
Paula Rodriguez-Otero et al.
CANCER TREATMENT REVIEWS (2021)
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
Bruno Paiva et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Early monoclonal protein decline pattern is an independent prognostic factor in patients with multiple myeloma
Limei Xu et al.
ANNALS OF HEMATOLOGY (2020)
Multiple Myeloma: Available Therapies and Causes of Drug Resistance
Vanessa Pinto et al.
CANCERS (2020)
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
Alejandro Medina et al.
BLOOD CANCER JOURNAL (2020)
Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: A model-based characterization approach
Belen P. Solans et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?
Susanna Gassiot et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
Laura Rosinol et al.
BLOOD (2019)
The impact of response kinetics for multiple myeloma in the era of novel agents
Yuting Yan et al.
BLOOD ADVANCES (2019)
Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma
Nidhi Tandon et al.
BLOOD ADVANCES (2019)
Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1
Laurent Garderet et al.
LEUKEMIA (2018)
Trends in overall survival and costs of multiple myeloma, 2000-2014
R. Fonseca et al.
LEUKEMIA (2017)
Establishing the Quantitative Relationship Between Lanreotide AutogelA®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors
Nuria Buil-Bruna et al.
AAPS JOURNAL (2016)
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
Bruno Paiva et al.
BLOOD (2016)
Utility of flow cytometry studies in the management of patients with multiple myeloma
Bruno Paiva et al.
CURRENT OPINION IN ONCOLOGY (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
New criteria for response assessment: role of minimal residual disease in multiple myeloma
Bruno Paiva et al.
BLOOD (2015)
Early Prediction of Disease Progression in Small Cell Lung Cancer: Toward Model-Based Personalized Medicine in Oncology
Nuria Buil-Bruna et al.
CANCER RESEARCH (2015)
A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment
R. Almufti et al.
ANNALS OF ONCOLOGY (2014)
Modern Therapy of Acute Lymphoblastic Leukemia
Renato Bassan et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients
Bruno Paiva et al.
BLOOD (2009)
Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients
Bruno Paiva et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics
Laurent Claret et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
分享论文
